Atorvastatin calcium: PLACE IN THERAPY(6)
Atherogenic dyslipidemia’ has been suggested to be a dyslipidemic syndrome characterized by specific abnormalities in the lipoprotein profile: borderline-high LDL-C levels, elevated triglyceride levels, low HDL-C levels and the presence of small, dense, LDL particles . These abnormalities often occur together and have been suggested to impart a risk of CAD at least equal to that of primary hypercholesterolemia (ie, increased LDL-C). Atorvastatin, with its unique ability to affect the lipoprotein fraction most available, may be a useful first-line agent for the treatment of this syndrome. Clinical trial results have shown that atorvastatin significantly lowers LDL-C and triglyceride levels, and raises HDL-C levels. Additionally, in one study, atorvastatin was reported to reduce small, dense, LDL particle size in patients with combined (mixed) hyperlipidemia ; however, further studies are required to verify this.
Patients with familial forms of dyslipidemia, such as FH, require large reductions in LDL-C levels, often in the range of 50% or greater, to reach treatment goals . The clinical data with atorvastatin in patients with heterozygous FH demonstrated that atorvastatin monotherapy (up to 80 mg/day) produced greater than 50% lowering of LDL-C levels . Similar data were obtained in patients with familial combined hyperlipidemia . Atorvastatin may thus be a useful first-line therapy for patients with heterozygous FH and familial combined hyperlipidemia. Atorvastatin may also provide useful adjunctive therapy with LDL apheresis in such patients and may have the potential to reduce the frequency of LDL apheresis sessions. Buy Asthma Inhalers Online